Abstract | OBJECTIVE: METHOD: The subjects were 16 outpatients with anergic bipolar depression. Fourteen had not responded to 4 weeks of treatment with at least 30 mg/day of tranylcypromine or 150 mg/day of imipramine, and two patients were crossed over because of intolerable side effects from the initial drug. The crossover medication was prescribed as in the initial double-blind study. RESULTS: CONCLUSIONS: The high rates of response to tranylcypromine in both the initial and crossover double-blind studies document the efficacy of MAOI treatment for anergic bipolar depression. Moreover, the results further illustrate the utility of MAOIs in tricyclic-resistant depressions.
|
Authors | M E Thase, A G Mallinger, D McKnight, J M Himmelhoch |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 149
Issue 2
Pg. 195-8
(Feb 1992)
ISSN: 0002-953X [Print] United States |
PMID | 1734739
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Tranylcypromine
- Imipramine
|
Topics |
- Adolescent
- Adult
- Ambulatory Care
- Bipolar Disorder
(drug therapy, psychology)
- Double-Blind Method
- Female
- Humans
- Imipramine
(therapeutic use)
- Male
- Middle Aged
- Personality Inventory
- Psychiatric Status Rating Scales
- Recurrence
- Tranylcypromine
(therapeutic use)
|